# Pembrolizumab and Monoclonal Antibody Therapy in Advanced Cancer

> **NCT02318901** · PHASE1,PHASE2 · TERMINATED · sponsor: **Western Regional Medical Center** · enrollment: 16 (actual)

## Conditions studied

- Advanced Cancer
- Breast Cancer
- Gastric Cancer
- Esophageal Cancer
- Colorectal Cancer

## Interventions

- **DRUG:** Pembrolizumab
- **DRUG:** Trastuzumab
- **DRUG:** ado-trastuzumab emtansine
- **DRUG:** Cetuximab

## Key facts

- **NCT ID:** NCT02318901
- **Lead sponsor:** Western Regional Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-10
- **Primary completion:** 2018-08
- **Final completion:** 2018-08
- **Target enrollment:** 16 (ACTUAL)
- **Why stopped:** PI no longer at sight. Results not collected
- **Last updated:** 2019-10-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02318901

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02318901, "Pembrolizumab and Monoclonal Antibody Therapy in Advanced Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02318901. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*